Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 41,648 shares, a drop of 17.1% from the February 26th total of 50,255 shares. Based on an average daily volume of 26,424 shares, the short-interest ratio is presently 1.6 days. Currently, 2.0% of the company’s shares are sold short.

Xenetic Biosciences Stock Performance

NASDAQ:XBIO opened at $2.72 on Monday. The company has a market cap of $6.23 million, a price-to-earnings ratio of -1.71 and a beta of 2.26. Xenetic Biosciences has a twelve month low of $1.90 and a twelve month high of $13.93. The stock has a fifty day simple moving average of $2.50 and a 200-day simple moving average of $2.86.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.30. The firm had revenue of $0.77 million for the quarter, compared to analysts’ expectations of $0.69 million. Xenetic Biosciences had a negative net margin of 90.09% and a negative return on equity of 51.27%. As a group, equities research analysts predict that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Xenetic Biosciences currently has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC bought a new position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned 0.60% of Xenetic Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 15.12% of the stock is owned by institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.